Current Edition

$1

Viatris, after closing massive West Virginia plant, sells it for $1

There will be no need to take a wrecking ball to Mylan’s former manufacturing plant in Morgantown, West Virginia. The former factory, which once housed …

Continue Reading →
Biocon

Another Samsung Bioepis? Biocon, Viatris mull merging biosimilar businesses

Samsung Bioepis represents the marriage of an Asian company and a Western drugmaker with a focus on biosimilars. Now, two other players are reportedly considering …

Continue Reading →
antibody drugs

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …

Continue Reading →
Biocon

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …

Continue Reading →
California

Viatris to close former Novartis site in California in January, lay off 75

Viatris has been busy with cost cuts over the last year, including shuttering a plant in West Virginia that had served as a staple of …

Continue Reading →
biopharma

Viatris shows no signs of growing pains in its ‘trough year,’ but one analyst has longer-term worries

Viatris CEO Michael Goettler may well consider this a “trough” year for his newly formed company. But only months after he made that declaration, Viatris …

Continue Reading →